Mylan Faces Patent Suit Over Generic Comtan
Orion announced the filing of the suit in a statement Monday, several weeks after Orion was notified that Mylan had filed an abbreviated new drug application with the U.S. Food and Drug Administration to make a generic version of Comtan.
The active ingredient in Comtan, which is marketed in the U.S. exclusively by Novartis AG, is entacapone. The drug is...
To view the full article, register now.